Berberine has been called "nature's Ozempic" and is touted for everything from fighting cancer to alleviating depression. This article separates the marketing hype from the evidence-backed benefits — and examines the one clinical scenario where berberine has the clearest role.
Table of Contents
- What is it? What are the claims?
- Sorting Hype from Demonstrated Benefits
- Metformin, Berberine, and Exercise
- Better Options
- References
What is it? What are the claims?
Berberine is a bright yellow alkaloid compound naturally found in several plants, including barberry, Oregon grape, goldenseal, and Chinese goldthread. It has been used for centuries in traditional Chinese medicine to treat conditions like diarrhea and gastrointestinal infections. More recently, it has drawn significant interest from researchers for its potential effects in a wide variety of other areas — particularly in metabolic health.
It is currently being investigated for its possible effects on blood sugar control, cholesterol levels, weight loss, cancer, and more. Social media has accelerated its popularity well ahead of what the clinical evidence can support — which makes an honest review of that evidence especially valuable.
Sorting Hype from Demonstrated Benefits
What does the current research show? How much of this is hype and how much is grounded in solid evidence?
Starting with cancer: in experiments, berberine has shown an ability to fight cancer cells in a petri dish of breast, colorectal, lung, prostate, and liver cancers [1]. It also appears to enhance the effectiveness of existing cancer treatments, in a petri dish [1].
But the research here is really early. It mostly involves seeing how cancer cells outside the body respond to berberine in the lab. Promising results at this level often don't translate into effective treatments when tested in humans. Far more clinical evidence is needed before drawing firm conclusions.
The data is simply not there yet.
Next, consider berberine's impact on blood cholesterol levels. Cholesterol is a concern because elevated levels of LDL cholesterol contribute to plaque build-up in arteries and increase the risk of heart attacks.
Separate meta-analyses of over 200 prospective cohort studies and randomized trials — including more than 2 million participants with over 20 million person-years of follow-up — have confirmed that higher LDL-c levels correspond to higher risk of heart disease [2].
Research has found berberine acts on several levels to help. It reduces how much cholesterol from food gets absorbed in the gut. It also has a dual impact on LDL receptors in the liver [3].
The liver is a key player in how the body regulates cholesterol levels. It has receptors that pull LDL cholesterol from the blood. Think of these receptors as little traps specifically built to capture molecules of LDL cholesterol. The more of these traps there are, the lower the levels of LDL cholesterol in the blood [4].
Berberine stimulates the liver to make more LDL receptors. At the same time, it reduces how much PCSK9 is made. This is a protein whose job is to break down LDL receptors [3].
So how much does this actually help in practice? A meta-analysis in 2018 looked at the results of 16 clinical trials. It found berberine reduced total cholesterol and LDL cholesterol, but the overall effect is relatively small. It also gave a slight boost to HDL (or good) cholesterol [5]. An updated meta-analysis in 2024 yielded similar results [6].
There is a caution from the researchers in the 2018 analysis, though. They note there are issues with study quality, and different individual studies had wide variation in results — a point worth keeping in mind [5].
Unfavorable cholesterol levels are just one component of what is known as metabolic syndrome. It is a cluster of risk factors that increase the odds of both heart disease and type 2 diabetes. Other important components include high blood sugar and obesity. There has been excitement about berberine's link to these two issues as well.
On blood sugar: one of the important effects of berberine is to activate AMPK [7].
AMPK is an enzyme that acts as a cellular energy sensor — a metabolic master switch. When it is activated, it drives a set of processes to restore energy balance. Normal levels of AMPK keep blood sugar levels healthy. Impaired AMPK function is an important contributor to type 2 diabetes.
This is also one of the core mechanisms by which metformin — a widely prescribed diabetes medication — works.
So how much can berberine help? A meta-analysis in 2021 examined the effects of berberine supplements in patients with type 2 diabetes across 46 trials. It found berberine lowered HbA1c levels by an average of 0.38% [8].
To put that in context: HbA1c stands for hemoglobin A1c. Checking this level in the blood gives a measure of average blood sugar over the past 2–3 months. A normal level is generally less than 5.7%. Between 5.7% and 6.5% is considered pre-diabetic. Above 6.5% is considered diabetic. A reduction of 0.38% is borderline clinically meaningful in this context.
In the same analysis, berberine also reduced fasting glucose and blood sugar levels measured two hours after a meal [8]. Researchers described the post-meal reduction as "remarkable" — and this was the strongest effect observed. It compares favorably to the impact of metformin in comparable populations.
An intriguing pilot study pushed this comparison even further. It put berberine and metformin head-to-head in a population with type 2 diabetes. Berberine outperformed metformin in this trial, reducing HbA1c by 1.99% vs. 1.43%, fasting glucose by 3.78 vs. 2.80 mmol/L, and post-meal glucose by 8.78 vs. 7.67 mmol/L. It also reduced triglycerides and cholesterol [9].
Does this mean it is time to switch from metformin to berberine for pre-diabetes or type 2 diabetes?
Not yet. Here is why. These results are intriguing, but there is a significant difference between berberine and metformin when it comes to the quality of evidence — and this distinction matters.
This is a point that is often lost online when people compare metformin to berberine.
There are much larger trials with better designs and longer follow-up periods for metformin when compared to berberine.
For instance, there is a trial tracking the impact of metformin on the incidence of diabetes over 10 years with thousands of participants [10]. Compare that to the head-to-head trial of berberine and metformin described above, which enrolled only 36 people and lasted just 3 months [9].
Furthermore, that study is an outlier. The meta-analyses, which group the results of multiple studies together, find a more modest impact for berberine. And the results of individual studies are wide-ranging.
The same can be said about risk profile. From results so far, berberine appears to be safe. But there is not yet the same level of long-term data available for it as there is for metformin.
All of this is why clinical guidelines recommend metformin for pre-diabetic and type 2 diabetic patients — not berberine. Metformin is well-established, effective, and safe.
Now for one last element of metabolic syndrome — obesity. Some influencers have been calling berberine "nature's Ozempic" for weight loss. Is there any truth to this?
A meta-analysis in 2020 examined the data across 12 studies on berberine's impact on weight loss. Berberine was found to reduce weight by 2.07 kg and BMI by 0.47 on average [11].
But a more recent meta-analysis — which included more studies — found a smaller number. Average weight loss was 0.84 kg, though it reached as high as 1.63 kg for one subgroup [12].
That is a relatively small effect. For comparison, the real Ozempic (semaglutide): a large randomized controlled trial found the average weight loss over 68 weeks was 15.3 kg — an effect size dramatically larger than berberine [13].
For patients pursuing meaningful weight loss, GLP-1 medications prescribed alongside a high-quality diet and regular exercise remain the evidence-based approach.
Metformin, Berberine, and Exercise
The discussion above has focused on berberine's impact on people who are pre-diabetic or have type 2 diabetes. But what about healthy adults? There was initial interest in metformin's potential benefits for non-diabetic populations — and the same question naturally arises for berberine.
The key promise was connected to aging. Remember how metformin boosts AMPK, just as berberine does? It was thought this could extend lifespan. But the research since those initial promising results has been disappointing. Metformin failed to extend lifespan when tested by the Interventions Testing Program [14].
And in humans, when the Diabetes Prevention Program tested metformin in high-risk but non-diabetic individuals, there was no benefit compared to a placebo for cancer rates, cardiovascular disease, or all-cause mortality over the 21-year follow-up period [15].
In other words, the evidence available today does not suggest metformin counters the effects of aging. It helps prevent diseases that cause early death. That is why it makes sense for pre-diabetics or people with type 2 diabetes to take it — and why it does not make sense for someone without those conditions to use it as a general supplement.
More troubling, there is now evidence that metformin can have negative effects. In a 2019 study where both groups were exercising, participants who took metformin improved their cardiovascular fitness by only half as much as those who took a placebo [16].
That finding was backed up by a 2022 study showing the same result. Metformin use reduced improvements in how well the body can use oxygen during exercise by half [17].
An additional concern is that metformin also lowers testosterone levels [18].
So does berberine fare any better? The evidence here is severely limited. But it looks like similar issues will arise with exercise. The underlying problem is this: when AMPK is ramped up, it acts to conserve energy in the body. One of the key ways it does this is to reduce protein synthesis — which is essential for muscle growth. So stimulating AMPK may limit muscle gains.
Is there evidence of this with berberine? The data is severely limited, but one study in mice found berberine decreased protein synthesis and led to a measurable reduction in muscle mass [19].
On the other hand, a more recent study in mice found a different result — berberine helped prevent muscles from shrinking. However, this was specifically in obese mice, where the metabolic context is very different from that of a generally healthy, exercising adult [20].
So, as with metformin, the clearest benefits of berberine are for those with pre-diabetes or type 2 diabetes. For otherwise healthy adults — particularly those who exercise regularly — berberine may be counterproductive. The potential to blunt cardiovascular fitness gains, reduce muscle protein synthesis, and lower testosterone levels means the risk-benefit profile looks unfavorable for healthy populations. This is the evidence-based rationale for why berberine is not included in MicroVitamin: for generally healthy people, those risks outweigh any theoretical benefit from AMPK activation.
Better Options
Here is where the clinical evidence points — and where berberine fits into the broader picture.
Lifestyle factors — exercise and a high-quality diet — are always the starting point and make a substantial, well-documented difference across all components of metabolic syndrome. But in some cases, even well-optimised lifestyle habits are not sufficient to bring blood sugar, cholesterol, or weight to target, and that is where evidence-based medications have an important role to play.
For controlling blood sugar, the first-line medication is metformin. It is well-established, it works, and it is very affordable.
This may change in coming years. GLP-1 medications like Ozempic have a powerful lowering effect on blood sugar. The downside has been their cost, but as that comes down, they may replace metformin as the first-line treatment for type 2 diabetes.
For now, GLP-1 medications remain the first choice for significant weight loss. They have been a genuine clinical advance in helping patients achieve and sustain meaningful reductions in BMI.
For elevated cholesterol, the initial treatment is typically low-dose hydrophilic statins such as rosuvastatin 5 mg or pravastatin 20 mg. When patients are intolerant to statins or their cholesterol is not adequately controlled, ezetimibe may be added — and it is also very affordable.
When those options are insufficient, PCSK9 inhibitors and the newer medication bempedoic acid come into consideration.
PCSK9 inhibitors are expensive, and bempedoic acid is under patent. This is where berberine may have a role.
If a patient is intolerant to statins, ezetimibe is not producing adequate results, and PCSK9 inhibitors or bempedoic acid are not financially accessible, berberine can be considered as a last-line adjunct.
It is a last resort because the cholesterol-lowering effect is much smaller compared to the other medications available, and we lack the long-term outcomes data that exists for established treatments. Statins, for example, have been robustly shown to reduce rates of heart disease and cardiovascular events compared to a placebo in large, long-term trials [21]. That same level of evidence does not yet exist for berberine — and it is the evidence that matters, not just the mechanism.
References
Below are the references cited in the order they appeared:
1. https://onlinelibrary.wiley.com/doi/10.1002/jbt.70073
2. https://pubmed.ncbi.nlm.nih.gov/28444290/
3. https://www.uptodate.com/contents/lipid-management-with-diet-or-dietary-supplements
4. https://www.ncbi.nlm.nih.gov/books/NBK519561/
5. https://pubmed.ncbi.nlm.nih.gov/30466986/
6. https://pubmed.ncbi.nlm.nih.gov/39640489/
7. https://www.sciencedirect.com/science/article/pii/S266703132100052X
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC8696197/
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC2410097/
10. https://pmc.ncbi.nlm.nih.gov/articles/PMC3135022/
11. https://pubmed.ncbi.nlm.nih.gov/32690176/
12. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.1013055/full
13. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
14. https://pmc.ncbi.nlm.nih.gov/articles/PMC5013015/
16. https://pmc.ncbi.nlm.nih.gov/articles/PMC6351883/
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC9321693/
18. https://pmc.ncbi.nlm.nih.gov/articles/PMC8740051/
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC2911075/
20. https://pubmed.ncbi.nlm.nih.gov/39930016/
21. https://www.cochrane.org/CD004816/VASC_statins-primary-prevention-cardiovascular-disease
Note: This article is for informational purposes only and is not a substitute for professional medical advice. Always consult with a qualified healthcare provider regarding your individual health needs.
